NUVB Insider Trading
Insider Ownership Percentage: 5.07%
Insider Buying (Last 12 Months): $1,985,500.47
Insider Selling (Last 12 Months): $0.00
Nuvation Bio Insider Trading History Chart
This chart shows the insider buying and selling history at Nuvation Bio by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Nuvation Bio Share Price & Price History
Current Price: $1.82
Price Change: ▼ Price Decrease of -0.055 (-2.94%)
As of 03/28/2025 04:59 PM ET
Nuvation Bio Insider Trading History
Nuvation Bio Institutional Trading History
Data available starting January 2016
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Read More on Nuvation Bio
Volume
1,431,289 shs
Average Volume
1,942,415 shs
Market Capitalization
$614.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.47
Who are the company insiders with the largest holdings of Nuvation Bio?
Who are the major institutional investors of Nuvation Bio?
Which institutional investors are selling Nuvation Bio stock?
During the last quarter, NUVB stock was sold by these institutional investors:
- Renaissance Technologies LLC
- Dimensional Fund Advisors LP
- Federated Hermes Inc.
- JPMorgan Chase & Co.
- Assenagon Asset Management S.A.
- Squarepoint Ops LLC
- XTX Topco Ltd
- Bank of America Corp DE
Which institutional investors are buying Nuvation Bio stock?
During the last quarter, NUVB stock was acquired by institutional investors including:
- FMR LLC
- Vanguard Group Inc.
- MPM Bioimpact LLC
- Millennium Management LLC
- Geode Capital Management LLC
- Algert Global LLC
- Northern Trust Corp
- Charles Schwab Investment Management Inc.
In the last year, these company insiders have bought Nuvation Bio stock:
- Xiangmin Cui (Director)
- Kim D Blickenstaff (Director)
- Robert Mashal (Director)
Learn More investors buying Nuvation Bio stock.